↓ Skip to main content

Dove Medical Press

A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer

Overview of attention for article published in OncoTargets and therapy, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
23 Mendeley
Title
A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer
Published in
OncoTargets and therapy, September 2015
DOI 10.2147/ott.s84636
Pubmed ID
Authors

Wei Jia, Guang-He Fei, Jie-Gui Hu, Xian-Wei Hu

Abstract

Lung cancer is one of the most commonly diagnosed clinical diseases. IL-6 is a multifunctional cytokine that is related to chemotactic factors and tumor biological regulation. -174G/C polymorphism in the promoter region of the IL-6 gene single-nucleotide polymorphism is the -174 position change from G to C. However, the relationship between the IL-6 gene polymorphism and prognosis of lung cancer is elusive. Therefore, the aim of this study was to evaluate the effect of -174G/C polymorphism on the prognosis of patients with non-small-cell lung cancer (NSCLC). DNA was extracted from the peripheral blood of 434 cases diagnosed with NSCLC by cytologic or histologic examination. Polymerase chain reaction-restriction fragment length polymorphism (NlaIII) was used to detect the genotype of -174G/C. Based on the functional activity of the IL-6 gene polymorphism, genotypes were divided into G vector (CG/GG) (high yield) and CC genotype (low yield). Prognosis of patients was analyzed and independent risk factors evaluated. A quantitative analysis of the degree of pain after diagnosis was performed to evaluate the correlations between gene polymorphisms and the degree of pain and use of analgesics. Survival analysis showed that survival of the patients carrying the G allele (CG/GG) was significantly lower than that of patients with CC genotype (42.31 versus 62.79 months; P=0.032). The IL-6 gene promoter region revealed the presence of polymorphic variants, which may be associated with changes in the gene transcription process that affect the level of serum cytokines. IL-6 -174G/C gene polymorphism is associated with a significant morphine equivalent daily dose (IL-6 GG, 69.61; GC, 73.17; CC, 181.67; P=0.004). Homozygous IL-6 -174C/C genotype carriers required higher doses of opioids than GG or GC carriers. Polymorphism of -174G/C in IL-6 is closely related to cancer pain in NSCLC patients, the use of analgesics, and survival prognosis. It is necessary to further confirm the related results and determine the underlying pathogenic mechanisms.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 22%
Student > Ph. D. Student 3 13%
Student > Bachelor 2 9%
Professor 2 9%
Researcher 2 9%
Other 4 17%
Unknown 5 22%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 17%
Medicine and Dentistry 4 17%
Biochemistry, Genetics and Molecular Biology 3 13%
Agricultural and Biological Sciences 3 13%
Business, Management and Accounting 1 4%
Other 2 9%
Unknown 6 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2015.
All research outputs
#18,427,608
of 22,829,083 outputs
Outputs from OncoTargets and therapy
#1,487
of 2,933 outputs
Outputs of similar age
#192,483
of 266,859 outputs
Outputs of similar age from OncoTargets and therapy
#50
of 100 outputs
Altmetric has tracked 22,829,083 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,933 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,859 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.